Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment

Eur Respir J. 2000 Jan;15(1):205-8. doi: 10.1183/09031936.00.15120500.

Abstract

Drugs are well known causes of eosinophilic lung disease. In many patients, symptoms increase slowly, pulmonary infiltrates and eosinophilia progress over weeks, and resolve upon withdrawal of the offending agent. Rarely, the disease presents like acute eosinophilic pneumonia with acute onset of symptoms and rapidly progressing infiltrates which may be associated with respiratory failure. This report describe a case of venlafaxine-induced acute eosinophilic pneumonia causing respiratory insufficiency that rapidly resolved upon institution of corticosteroid treatment. This 5-hydroxytryptamine and noradrenaline reuptake inhibitor was previously not known to cause lung or peripheral blood eosinophilia. Considering the increasing use of this class of medication physicians have to be aware of this life-threatening and fully reversible complication.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adult
  • Antidepressive Agents, Second-Generation / adverse effects*
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Biopsy
  • Cyclohexanols / adverse effects*
  • Cyclohexanols / therapeutic use
  • Depressive Disorder, Major / drug therapy*
  • Humans
  • Lung / pathology
  • Male
  • Prednisone / administration & dosage
  • Pulmonary Eosinophilia / chemically induced*
  • Pulmonary Eosinophilia / diagnosis
  • Pulmonary Eosinophilia / drug therapy
  • Respiratory Insufficiency / chemically induced*
  • Respiratory Insufficiency / diagnosis
  • Respiratory Insufficiency / drug therapy
  • Tomography, X-Ray Computed
  • Venlafaxine Hydrochloride

Substances

  • Antidepressive Agents, Second-Generation
  • Cyclohexanols
  • Venlafaxine Hydrochloride
  • Prednisone